Blurbs

Nephros (NEPH) Receives a Buy from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Nephros (NEPHResearch Report) yesterday and set a price target of $5.00. The company’s shares opened today at $1.72.

Vendetti covers the Healthcare sector, focusing on stocks such as Aethlon Medical, ReShape Lifesciences, and Guardion Health Sciences. According to TipRanks, Vendetti has an average return of 3.1% and a 36.77% success rate on recommended stocks.

Currently, the analyst consensus on Nephros is a Moderate Buy with an average price target of $5.13.

See the top stocks recommended by analysts >>

Based on Nephros’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.19 million and a GAAP net loss of $2.03 million. In comparison, last year the company earned a revenue of $2.74 million and had a GAAP net loss of $596 thousand

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Renal Products segment comprises of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Read More on NEPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos